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Introduction   
Prostate cancer (PC) is a major health issue in Western countries, representing the most frequent 
tumour and the second leading cause of cancer-related deaths among males 
1
.  
In the natural history of the majority of advanced PC patients, it is possible to identify two phases. In 
the first so-called castration-sensitive prostate cancer (CSPC) phase, the androgen receptor (AR) 
pathway plays a fundamental role in disease growth and progression. As a consequence, tumour cells 
are highly responsive to the reduction in serum testosterone levels and androgen-deprivation therapy 
(ADT), achieved by either surgical or medical castration, which represents the mainstay of therapy. 
Although ADT induces biochemical and clinical responses in more than 90% of patients, after a 
median of 24-36 months, all progress to the second phase of the disease, called castration-resistant 
prostate cancer (CRPC) 
2
.  
CRPC, previously defined as hormone-refractory prostate cancer, is now understood to still be 
androgen dependent. Multiple mechanisms of resistance contribute to the progression to castration 
resistant disease, and the AR remains an important driver in this progression. 
Recently, the therapeutic strategy for CRPC patients radically changed due to improved knowledge of 
PC biology and progression mechanisms. At present, we know that AR plays a critical role in CRPC 
and the interplay between bone resident and prostatic cancer cells is responsible for metastatic 
progression in bone 
3,4
.  
Consequently, several new drugs able to increase overall survival (OS) have been introduced in daily 
clinical practice for the management of metastatic CRPC (mCRPC). Results of randomised phase III 
trials showed the activity of an immunotherapeutic agent (sipuleucel-T) 
5
, two next-generation 
hormonal treatments (abiraterone acetate [AA] 
6,7
 and enzalutamide 
8,9
), an innovative taxane 
(cabazitaxel) 
10, and an α particle-emitting agent (radium-223) 11. 
Moreover, the last three years saw a revolutionary change in the treatment paradigm of metastatic 
CSPC (mCSPC). Recent findings demonstrated that in patients with de novo mCSPC, the addition of 
chemotherapy with docetaxel (DOC) to ADT significantly improves OS compared to ADT alone 
12,13
. 
Additionally, two recent studies (LATITUDE and STAMPEDE) performed in the same disease phase 
established that adding AA to ADT significantly increases OS in mCSPC 
14,15
. 
Due to the evolution of metastatic prostate cancer treatment scenarios, clinicians presently face 
important therapeutic challenges. The main challenge is the choice of the best treatment sequencing for 
each specific patient. In this context, we have only some limited retrospective data to guide decision-
making in patients experiencing disease progression after DOC or AA treatment for mCSPC. 
This review provides an overview of the therapeutic options available to both mCSPC and mCRPC 
patients and offers some clinical and biological insights to select the best treatment for patients with 
progressive disease progression after mCSPC treatment with DOC or AA.  
Evidence for docetaxel and abiraterone use in mCSPC 
a) Docetaxel 
GETUG-AFU 15 trial 
The GETUG-AFU 15 randomised phase III trial enrolled patients with newly diagnosed mCSPC who 
were randomised to receive ADT with or without DOC 75 mg/sqm IV every three weeks for a 
maximum of nine courses 
16
. 
The results of the trial, which enrolled 385 patients between October 2004 and December 2008, were 
first published in 2013 after a median follow-up of 50 months. The experimental arm showed 
significantly longer biochemical progression-free survival (PFS) compared to the standard treatment 
arm  (median 22.9 and 12.9 months, respectively; p = 0.005); similar findings were observed in terms 
of the clinical PFS, which was significantly longer in the DOC arm (median 23.5 months) than in the 
ADT-alone arm (median 15.4 months; p = 0.015). This clear PFS advantage did not lead to a 
significant OS improvement: the median OS in the chemotherapy group and in the ADT-alone group 
was 58.9 months and 54.2 months, respectively (p = 0.955). 
After the publication of the CHAARTED trial results (see below), an updated analysis of the GETUG-
AFU 15 trial was published in 2016 
17
. This analysis, based on a longer follow-up than the first report 
(83.9 months), aimed to assess the impact of metastatic burden by applying the same criteria of the 
CHAARTED trial for the identification of patients with high vs low volume of disease (see below). 
Although in the overall population there was an absolute difference of 13.5 months in terms of median 
OS in favour of the chemotherapy group (62.1 vs 48.6 months), this did not reach statistical 
significance (HR: 0.88; p = 0.3). No statistically significant differences were observed between the two 
treatment groups according to the metastatic burden and the timing of the metastases diagnosis (after 
radical local treatments or at diagnosis). 
CHAARTED trial 
The CHAARTED randomised phase III trial enrolled patients with newly diagnosed mCSPC who were 
randomised to receive ADT with or without DOC 75 mg/sqm IV every three weeks for a maximum of 
six courses
12
.  
The results of the CHAARTED trial, which enrolled 790 patients between July 2006 and December 
2012, were published in 2015 after a median follow-up of 28.9 months. The experimental arm was 
clearly superior to the standard arm in terms of both PFS (median 20.2 vs 11.7 months; HR 0.61; p < 
0.001) and OS (median 57.6 vs 44.0 months; HR 0.61; p < 0.001). The differences were more 
significant and impressive for the group of patients with high disease volume (defined as having 
visceral metastases and/or ≥ 4 bone lesions with ≥ 1 beyond the vertebral bodies and pelvis) who 
showed a gain in median OS of 17.0 months if they had received DOC and ADT instead of ADT alone 
(49.2 vs 32.2 months; HR 0.60; p < 0.001). In the group of patients with low-volume disease, no 
statistically significant differences in OS were observed, although the reduction of death risk was quite 
similar to that observed in the high-volume group, HR 0.60 (95% CI: 0.32-1.13), p = 0.11, suggesting 
that the low number of deaths made the results premature. An update of the survival results with a 
longer follow-up confirmed the large advantage for the experimental arm in the high-volume patients 
but failed to show reduction in the death risk in favour of DOC treatment for the patients with low-
volume disease, HR 1.04 (95% CI: 0.70-1.55), p = 0.86 
18
.  
The non-significant result of the CHAARTED trial in the low-volume subgroup of patients may depend  
on the lower mortality compared to the high-volume disease patients, to immature survival end-point 
and on the small number of patients, with inadequate power to detect an OS benefit. 
By combining the disease burden and the metastatic timing, the combined results from the 
CHAARTED and GETUG-AFU 15 trials clearly supported a survival advantage in metastatic “de 
novo” patients with high-volume disease with an OS gain in the DOC + ADT arm compared to the 
ADT-alone arm, 48.0 months vs 33.1 months; HR 0.63 (95% CI: 0.49-0.81); p = 0.0004 
19
. 
STAMPEDE trial 
STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug 
Efficacy), a multi-centre, open-label, multi-arm, multi-stage randomised trial, aimed to evaluate if the 
addition of new treatments to the standard of care (SOC, ADT ± radiotherapy) improves the OS in men 
with high-risk locally advanced prostate cancer or mCSPC. The main characteristic of this trial is its 
ability to test treatments that could potentially be efficacious in mCSPC by opening new treatment 
arms to be compared to the standard treatment arm over time
20
. The comparison of one or more new 
treatment arms vs SOC may be considered a new randomised study and the sample size is defined 
according to a specific statistical design, with primary endpoint OS. 
The results of the STAMPEDE trial were published in 2016. The four treatment arms included: 
standard of care only (SOC-only), SOC plus zoledronic acid (ZA), SOC plus DOC, and SOC plus ZA 
and DOC
13
.  
The experimental treatments consisted of ZA given at the standard 4 mg dose every three weeks for six 
cycles, then every four weeks until 2 years and/or DOC at the standard dose of 75 mg/m2 every three 
weeks for six cycles with prednisolone 10 mg daily. A total of 2962 men were randomly assigned to 
the four groups between October 2005 and March 2013. After a median follow-up of 43 months, the 
median OS was 71 months  in the SOC-only arm, not reached  in the SOC + ZA arm (HR 0.94, 95% 
CI: 0.79-1.11; p = 0.450), 81 months  in the SOC + DOC arm (HR 0.78, 95% CI: 0.66-0.93; p = 0.006), 
and 76 months  in the SOC + ZA + DOC arm (HR 0.82, 95% CI: 0.69-0.97; p = 0.022). From these 
results, it was clear that the addition of ZA did not improve OS, while the addition of DOC led to a 
clear OS advantage. By selecting the population with metastasis (1817 patients), the results were 
confirmed, with a median OS of 45 months  in the SOC-only arm, 46 months  in the SOC + ZA arm 
(HR 0.93, 95% CI: 0.77-1.11; p = 0.416), 60 months  in the SOC + DOC arm (HR 0.76, 95% CI: 0.62-
0.92; p = 0.005), and 55 months  in the SOC + ZA + DOC arm (HR 0.79, 95% CI: 0.66-0.96; p = 
0.015).  
In terms of failure-free survival, the addition of ZA only to SOC did not lead to a risk reduction (HR 
0.92, 95% CI: 0.81-1.04; p = 0.198), while the addition of DOC to SOC led to a statistically significant 
risk reduction either without ZA (HR 0.61, 95% CI: 0.53-0.70; p = 0.413 x 10-13) or with ZA (HR 
0.62, 95% CI: 0.54-0.70; p = 0.134 x 10-12). In a metastatic setting, DOC significantly reduced the risk 
of failure (HR 0.61, 95% CI: 0.53-0.71; p = 0.283 x 10-10). 
b) Abiraterone acetate 
LATITUDE trial 
The LATITUDE trial enrolled high-risk newly diagnosed mCSPC patients who were randomised to 
receive either ADT plus AA 1000 mg daily plus prednisone (5 mg daily) or ADT plus dual placebos
14
. 
The definition of high-risk disease required at least two of the three following factors: a Gleason score 
of 8 or more, at least three bone lesions, and the presence of measurable visceral metastases. The trial 
enrolled 1199 patients from February 2013 to December 2014. 
The results of the LATITUDE trial were published after a planned interim analysis performed after a 
median follow-up of 30.4 months. The OS was significantly longer in the experimental arm than in the 
control arm (median not reached vs 34.7 months; HR 0.62; 95% CI: 0.51-0.76; p < 0.001), while the 
median radiographic PFS was 33.0 months in the AA arm and 14.8 months in the ADT-only arm (HR 
0.47; 95% CI: 0.39-0.55; p < 0.001). 
STAMPEDE trial 
The results of the comparison between the arm with SOC plus AA and the arm with SOC alone within 
the STAMPEDE trial development 
15
 were published in 2017. In the experimental arm, the patients 
received SOC plus daily AA at a standard dose of 1000 mg with 5 mg prednisolone.  
A total of 1917 patients were randomised between the two groups between November 2011 and 
January 2014. At a median follow-up of 40 months, there was a reduction of risk of death of 27% in 
favour of the experimental arm (HR 0.63; 95% CI: 0.52-0.76; p < 0.001) with a 3-year survival of 83% 
compared to 76% in the SOC-only group. Considering the 1002 patients with metastatic disease at 
entry, the HR for death was 0.61 (95% CI: 0.49-0.75). The HR for treatment failure was 0.29 (95% CI: 
0.25-0.34; p < 0.001), with a confirmed efficacy of AA in the metastatic patients (HR 0.31; 95% CI: 
0.26-0.37). 
c) Meta-analyses 
Docetaxel 
In 2015, Vale et al. 
21
 published a meta-analyses based on published data regarding the potential 
advantage of adding DOC or bisphosphonates to the standard of care in patients with localised or 
metastatic CSPC. In a metastatic setting, they analysed the results of the GETUG-AFU 15 trial, 
CHAARTED trial, and STAMPEDE trial and concluded that the addition of DOC to ADT led to an 
absolute improvement in the 4-year survival of 9% (95% CI: 5-14), with a reduction in the death risk of 
23%, with an HR of 0.77 (95% CI: 0.68-0.87; p < 0.0001), while in terms of failure-free survival, the 
reduction in the absolute 4-year failure rates was 16% (95% CI: 12-19), with an HR of 0.64 (95% CI: 
0.58-0.70; p < 0.0001).  
Meta-analysis by Tucci et al. (2016) evaluated only the addition of DOC in the group of mCSPC 
patients 
22
. Their results were quite similar: the administration of DOC was associated with a 
statistically significant OS benefit (HR 0.73; 95% CI: 0.60-0.90; p = 0.002). In the patients with high-
volume disease, the HR was 0.67 (95% CI: 0.51-0.88), while in the patients with low-volume disease, 
the HR was 0.80 (95% CI: 0.49-1.32). In terms of PFS, treatment with chemotherapy reduced the 
progression risk of the mCSPC patients by 27% (HR: 0.63; 95% CI: 0.57-0.70; p < 0.001). 
Because both meta-analyses demonstrated a lack of statistically significant heterogeneity among the 
three trials with DOC, their findings clearly supported the use of DOC in mCSPC. 
Abiraterone acetate 
The STOPCAP report 
23
, based on a framework for adaptive meta-analysis, summarised the results of 
the LATITUDE and STAMPEDE trials but also planned to take into account the potential impact of the 
results of PEACE-1, another trial testing the addition of AA and DOC to ADT in mCSPC that is still 
ongoing. Based on the PEACE-1 recruitment information available at the time this report was 
published, the available trials represent 82% (2201/2677) of all patients randomised to AA plus ADT 
vs ADT.  
The meta-analysis showed a 14% absolute improvement in 3-year OS, with a 38% reduction in the risk 
of death in favour of AA (HR 0.62, 95% CI: 0.53-0.71, p = 0.55 x 10-10). Similarly, the addition of 
AA to ADT produced a 28% absolute clinical/radiological PFS improvement at 3 years, with a 55% 
reduction in the progression risk (HR = 0.45, 95% CI: 0.40-0.51, p = 0.66 x 10-36). 
In this meta-analysis, there was no evidence of statistical heterogeneity between the trials, and the 
results supported the use of AA in mCSPC patients. 
d) Comparison between Abiraterone and Docetaxel 
Although not planned to test a direct comparison between the two treatment strategies according to a 
formal hypothesis, the STAMPEDE multi-arm, multi-stage platform protocol provides the only direct, 
randomised comparative data of standard of care (SOC) + AA versus SOC + DOC in mCSPC 
patients.
24
 This study showed no evidence of a difference in OS (HR 1.16; 95% CI: 0.82-1.65) or 
prostate cancer-specific survival (HR 1.02; 95%CI: 0.70-1.49), nor in other important outcomes such as 
symptomatic skeletal events (HR 0.83; 95% CI: 0.55-1.25) between the two treatments, suggesting that 
both currently remain viable new standard-of-care. 
Post-progression treatments after docetaxel and abiraterone 
The use of DOC and AA in mCSPC patients affects the subsequent treatments for mCRPC and, to date, 
there are little data on the efficacy and tolerance of post-progression therapies.  
In the GETUG-AFU 15 trial, most of the patients treated upfront with ADT and DOC for mHSPC 
(245/345) received at least one post-progression treatment. A recent paper analysed the outcomes of 
patients who received one life-prolonging agent for mCRPC
25
.  
Among the 24 patients who received a DOC rechallenge as a first-line treatment for mCRPC, 4 out of 
the 20 evaluable (20%) had a PSA decline ≥ 50%: this biochemical response rate was lower than 
observed in the patients enrolled in the ADT control arm (38%), although the difference did not 
achieve statistical significance (p = 0.14). The patients treated with DOC rechallenge showed a median 
biochemical progression-free survival of 4.1 months (95% CI: 1.3-4.9). Considering the cumulative 
analysis of the patients who received DOC either in first- or second-line treatment, a PSA decline ≥ 
50% was observed in 4/29 patients (14%) previously treated with ADT plus DOC (p = 0.07 vs DOC 
activity in the ADT control arm). It is noteworthy that the rate of patients who received a DOC 
rechallenge in the GETUG-AFU 15 trial was significantly lower compared to the CHAARTED trial, 
where 50% of the patients (191/385) received DOC after progression. Among the 10 patients who were 
treated with AA or enzalutamide at disease progression after DOC, only six were evaluable, with a rate 
of PSA decline ≥ 50% of 67%. However, this report had limited value in supporting the decision-
making process in a first-line mCRPC setting. In fact, the authors did not distinguish between those 
patients treated at the time of castration-resistance occurrence and those who received DOC 
rechallenge in subsequent treatment lines. Moreover, the number of patients evaluated was very 
limited, with a relevant number of cases not evaluable for biochemical response. Nevertheless, the 
authors concluded that at the occurrence of mCRPC, DOC rechallenge had limited activity in a very 
small number of patients while the new hormone agents maintained their efficacy.  
Recently, Francini et al. retrospectively evaluated a cohort of 102 patients treated with first-line AA or 
E for mCRPC, 52 of which had received DOC in mCSPC setting
26
. No statistically significant 
difference in any of the evaluated outcomes was observed in patients treated with ADT + DOC and 
those treated with ADT alone in mCSPC setting. Deaths in the ADT+DOC group were 12 versus 21 in 
the ADT alone, after a median follow-up of 24.4 and 29.8 months, respectively. 
Another study retrospectively evaluated the outcomes of first-line treatments in 136 mCSPC patients 
who had progressed after DOC plus ADT. In patients treated with new-generation hormonal therapies, 
the median radiological PFS was 9.0 months  compared to 3.0 months  observed in those who did not 
receive new-generation hormonal treatments (p = 0.024) 
27
.  
No data are yet available from the literature concerning the outcomes of life-prolonging agents after 
AA administered in a mCSPC setting.  
Drivers for decision-making 
a) Biological knowledge 
The evolving treatment landscape of metastatic PC is due to an expanded comprehension of the 
biological drivers that cause disease progression and particularly induce the shift from hormone-
sensitive to castration-resistant disease.  
At present, two progression models have been considered to describe the biological processes 
sustaining the occurrence of castration-resistant disease: the adaptation model and the clonal model 
28
. 
In the adaptation model, it is postulated that progression to CRPC is not due to a true androgen-
independence but is induced by the adaptation of androgen receptor (AR)-dependent PC cells to a 
micro-environment characterised by low androgen levels. 
Although androgen-deprivation treatment can cause a significant reduction in serum androgen levels, 
tumour cells could change the AR conformation, so that reduced androgen levels could stimulate it and 
produce androgens essential for their proliferation.  
The processes implicated in these androgen-deprivation therapy-resistance events consist of ligand-
dependent AR activation (AR overexpression or mutation, AR gene amplification, intratumoral 
androgen production) and ligand-independent AR activation (expression of AR splice variants, 
inactivation of retinoblastoma tumour suppressor protein (RB), upregulation of transcriptional AR co-
activators) 
28,29
. 
However, although AR is necessary for neoplastic progression, mechanisms not dependent from AR 
play a critical role in the treatment of CRPC patients. In this context, preclinical evidence showed that 
prostatic cancer cell lines (DU145 and PC3 cells) derived from hormone-sensitive metastatic tumours 
are able to induce the development of castration-resistant xenograft neoplasms in cases of AR 
signalling pathway absence 
30
. Adaptation mechanisms independent from AR mainly include epithelial-
mesenchymal transition and apoptosis inhibition 
29,31
 
32
. In particular, B-cell CLLC/lymphoma 2 (BCL-
2) is an anti-apoptotic protein able to interfere with the activation of caspases cascade, responsible for 
apoptosis, through the inhibition of the discharge of cytochrome C by the mitochondria of the cells 
33
. 
In physiological situations, epithelial prostatic cells do not express BCL-2. Preclinical data 
demonstrated that androgen-deprivation treatment is able to provoke the shift from hormone-sensitive 
to CRPC also inhibiting cellular apoptosis through the increase of BCL-2 expression in PC cells 
34
. 
AR-dependent and -independent mechanisms of progression can be the result of neoplastic cell 
adaptation to a low testosterone environment, but they also may be found in metastatic hormone-naïve 
patients not yet treated with androgen-deprivation therapy 
28
. 
This biological evidence allows us to assume that adaption theory is not the only process behind the 
progression to castration-resistant prostate carcinoma.  
The selection model states that prostate cancer is characterised by cellular clones with different grades 
of androgen dependence that are present before androgen-deprivation starts and that the development 
of the castration-resistance state is related to clonal selection and the further growth of pre-existing 
androgen-independent clones 
28
. 
Preclinical evidence demonstrated that in physiological conditions, the prostate gland is mainly 
composed of three kinds of epithelial cells: luminal cells, basal intermediate cells, and basal cells 
35
. 
These cells, present at various differentiation stages in prostatic cancer, have different AR expression 
and consequently different sensibilities to androgen-deprivation 
36
.  
Epithelial luminal cells are characterised by the presence of AR enzymatic machinery and high levels 
of AR expression, but in basal cells, it is possible to find only small AR concentrations. A preclinical 
study showed that androgen-deprivation therapy kills most luminal cells; however, this treatment is 
almost completely ineffective against basal cells 
37
. Hormonal therapy reduces luminal cells and 
favours the expansion of basal cells and basal intermediate cells 
38
.   
This biological evidence shows that prostatic carcinoma is a heterogeneous disease since the hormone-
sensitive phase, in which the shift to the castration-resistant phase is due to the coexistence of AR-
positive and AR-negative cells and mechanisms of progression both dependent and independent from 
AR 
28
.  
Because of this strong biological basis, the DOC activity in association with hormone therapy in 
advanced CSPC does not surprise. In fact, chemotherapy in combination with castration induces the 
inhibition of the growth of AR-independent cellular clones, provoking the death of cells before the 
occurrence of multiple resistance mechanisms 
22
. 
In this context, the main activity of taxanes on cellular mitosis is characterised by their capability to 
provoke the phosphorylation of BCL-2. This process induces the inactivation of BCL-2 favouring the 
apoptosis of neoplastic cells 
39
. 
In addition, taxanes have a peculiar mechanism of action that allows their synergistic activity with 
ADT. These drugs are able to interfere not only with AR-independent mechanisms of progression but 
also with the AR signalling pathway
40
.  
Taxanes inhibit AR nuclear translocation and gene expression through interference with microtubule 
polymerisation
41
. Furthermore, taxanes induce an improved expression of a transcriptional repressor of 
AR, the forkhead box 1 (FOX01), causing the blockage of neoplastic progression 
42
.  
Finally, taxanes are able to interfere with one of the fundamental ligand-independent resistance 
mechanisms, the lack of function of RB. An estimated 25-50% of PC patients face an inactivation of 
RB that promotes the progression of neoplastic cells during ADT. Preclinical data showed that taxanes 
are more active in prostatic cancer cells with RB deficiency
43
. 
At present, we know that the heterogeneity of PC in terms of both cellular subclones and mechanisms 
of resistance increases during the shift from the castration-sensitive to the castration-resistant phase of 
disease, particularly in rapidly progressing disease, leading to an increase in resistance mechanisms 
bypassing the AR pathway 
35
.   
We believe that these biological factors should guide the decision-making process, especially in 
mCRPC patients with more aggressive disease, such as those with poor ADT response and short PSA-
doubling time at progression. In these patients, taxanes administration could be the best therapeutic 
option, due to the capability of these drugs to interfere with several steps of resistance mechanisms. In 
this context, in patients already treated with DOC for mCSPC and rapidly progressing, the treatment of 
choice could be cabazitaxel. In fact, although there is no direct randomized evidence supporting this 
preference, these patients are most likely to be resistant to DOC and new-generation hormonal therapy. 
Cabazitaxel has a peculiar mechanism of action with a unique strength. It is potentially able to 
overcome resistance mechanisms to both DOC and new-generation hormonal therapy. In fact, 
preclinical evidence showed that cabazitaxel is active in cellular lines resistant to DOC 
44
 and has 
superior antitumour activity compared to DOC in enzalutamide-resistant tumours
45
.  
On the other hand, increasing experimental evidence suggests a possible cross-resistance between AA 
and enzalutamide. Although prospective randomised trials are needed to prove the predictive value of 
AR-V7 expression, the occurrence of this AR splice variant seems to influence the activity of AA and 
enzalutamide, which is significantly reduced, but not that of taxanes 
46-49
  
b) Disease control by previous treatment line  
The timing of progression occurrence is usually considered an indicator of resistance to a specific 
treatment and may influence the choice of subsequent therapy. Thus, all pivotal trials assessing new 
second-line drugs have carefully described their efficacy according to first-line PFS.  
In the COU-AA-301 trial, the effect of AA was similar between the prognostic groups according to the 
time of the last dose of DOC to the first dose of AA (≤ 3 months vs > 3 months) : in the patients treated 
within 3 months from the last dose of DOC, the median OS was 15.0 (95% CI: 13.7-17.4) compared to 
16.1 months median OS observed in the patients who started AA > 3 months after the last dose of DOC 
50
. 
In the case of cabazitaxel, this agent maintained its efficacy regardless of the time since the last DOC 
exposure, showing a survival advantage even in patients with shorter (< 3 months) PFS from previous 
DOC treatment or in patients progressing on DOC first-line therapy 
10
.  
Regarding the DOC rechallenge, PFS of first-line treatment has been considered a variable that can 
predict the potential ability of this strategy to prolong disease control. Loriot et al. showed a 
statistically significant correlation between the treatment-free interval since the last cycle of DOC-
based chemotherapy and the efficacy of subsequent rechallenge with DOC, which appeared higher as 
longer was the interval since the last cycle of DOC 
51
. Similar results were observed by Caffo et al. 
52
. 
Their retrospective analysis showed that the time from the previous administration of DOC was 
predictive of the response to a rechallenge, together with the time slope-log PSA and the response to 
the previous cycle. Most studies evaluating the DOC rechallenge strategy after first-line DOC reported 
good disease control in patients with first-line PFS longer than 6 months
52,53
. 
c) PSA doubling time 
A short PSA doubling time is a well-known prognostic factor, associated with more aggressive disease 
and consequently with poor outcomes in all phases of progressive prostatic cancer.  
A retrospective study enrolling 379 patients with biochemical recurrence after radical prostatectomy 
showed that PSA-DT (< 3.0 vs 3.0-8.9 vs 9.0-14.9 vs ≥ 15.0 months) represented a significant risk 
factor for prostate-specific mortality 
54
. A nomogram concerning chemotherapy-naïve patients with 
progressive mCRPC highlighted that a short PSA-DT represented a risk factor for poor survival 
55
. 
Although there is consensus on the relationship between PSA-DT and disease aggressiveness, there is 
no agreement on the cut-off level of PSA-DT able to identify mCRPC patients with different outcomes. 
In the TAX 327 trial, a PSA-DT < 55 days was related to shorter survival 
56
. In a real-life retrospective 
analysis, Oudard et al. used a PSA-DT cut-off of 45 days. In their report, this PSA-DT value identified 
two groups of patients with a statistically significant different OS (median 16.5 and 26.4 months for 
shorter and longer PFS, respectively) 
57
. In another retrospective study enrolling 224 mCRPC patients, 
the optimal cut-off level of PSA-DT for survival stratification was 70 days; patients with a PSA-DT < 
70 days had a median OS of 11 months compared to the median OS of 19 months in patients with PSA-
DT > 70 days 
58
.  
A trial testing the role of a potent inhibitor of osteoclast activity, denosumab, for the prevention of 
skeletal disease progression in non-metastatic CRPC patients showed shorter bone metastases-free 
survival in patients with PSA-DT < 8 months 
59
.  
d) Metastatic involvement 
The mCRPC patients are a heterogeneous population according to several factors related to the PC 
metastases localisation, both before and following treatments, and the patients’ characteristics. Several 
prognostic factors, including the number and location of bone metastases, visceral metastases, the 
Gleason score, performance status, baseline PSA or its decline ≥ 50% following treatment, and alkaline 
phosphatase, have been evaluated but not directly compared in the era of new-generation therapies 
60,61
. 
In the case of DOC treatment, visceral metastases, pain, anaemia (Hb < 13 g/dL), bone scan 
progression, and prior estramustine were considered independent prognostic factors able to predict the 
response to therapy by categorisation into three risk groups: low (0 or 1 factor), intermediate (2 
factors), and high (3 or 4 factors), showing significantly different OS (with a median of 25.7, 18.7, and 
12.8 months, respectively) 
62
.  
Among the aforementioned variables, the presence of visceral metastases (lung or liver metastases) is 
usually perceived as one the most important signs of aggressive disease and worse prognosis. The rate 
of visceral metastases among the patients enrolled in the mCRPC second-line pivotal studies ranged 
from approximately 11% in the case of new hormone agents to 25% in the case of cabazitaxel 
6,8,10
.  
Regarding the special population of patients with visceral metastases, in the COU-AA-301 trial, the 
experimental treatment reduced the risk of death by 21%, corresponding to an absolute survival benefit 
of 4.6 months compared to the placebo arm, which did not achieve statistical significance (HR = 0.79; 
95% CI: 0.60-1.05; p = 0.102) 
63
.  
Similarly, in the AFFIRM trial, the subgroup analysis showed a death reduction of 22% in the mCRPC 
patients with visceral metastases treated with enzalutamide: the median OS was 13.4 months in the 
experimental arm compared to 9.5 months in the control arm 
8
.  
No analysis specifically addressing the efficacy of cabazitaxel in patients with visceral metastases is 
available from the TROPIC trial, although the study forest plot suggested that this new-generation 
taxane produced a clear survival benefit in patients with measurable disease with a 32% death 
reduction.  
e) Symptoms 
The occurrence of symptoms in mCRPC patients usually reflects a more advanced disease and/or a 
more aggressive disease. Nevertheless, the presence/absence of symptoms (for example, pain) 
influenced the treatment choice, since this variable was considered among the eligibility criteria in the 
first- and second-line pivotal trials. AA and enzalutamide may be used only in asymptomatic or mildly 
symptomatic patients when these agents are used in a first-line setting 
64,65
 while they can be used in all 
mCRPC patients regardless of the presence of symptoms when they are used in later treatment lines 
6,8
. 
In the case of cabazitaxel, the TROPIC trial enrolled mCRPC patients with or without symptoms 
10
 
while the ALSIMPCA trial with radium-223 required the presence of symptoms to enrol mCRPC 
patients 
11
.   
In the TROPIC trial, which used the McGill-Melzack scale to rate pain presence, 46% of the patients in 
the cabazitaxel arm were symptomatic at the baseline; in this group of patients, the reduction of death 
risk was 23% in favour of those treated with cabazitaxel 
10
. 
In the COU-AA-301 trial, which adopted the Brief Pain Inventory to identify symptomatic patients, the 
rate of patients with a pain score ≥ 4 at the baseline was 32.2%; in these symptomatic patients, AA 
administration led to an absolute median OS increase of 3.7 months (12.6 vs 8.9 months), reducing the 
risk of death by 32% 
6
.  
Similar results were observed in the AFFIRM trial, which used the same scale for pain assessment. In 
this study, the reduction of death risk in symptomatic patients treated with enzalutamide was 29%, with 
an absolute increase in terms of median OS of 3.3 months 
8
. 
The ALSYMPCA trial, which adopted the WHO ladder to assess cancer pain, enrolled only 
symptomatic patients (32% with a score of 3). When the agent was administered after DOC, the 
reduction in death risk was 30%, with a median OS of 14.4 months and 11.3 months in the 
experimental and control arm, respectively 
66
.  
f) Cross-resistance among active agents 
Radium-223 exerts its anticancer activity via direct cell damage by alpha-particle emission, while, as 
underlined before, the other life-prolonging agents in mCRPC act on AR. However, in the case of 
taxanes, their interference in microtubule polymerisation hinders AR nuclear migration 
41
 and is 
alternatively able to inhibit cancer cell mitosis, and in the case of new-generation hormonal agents, AR 
machinery is the only direct or indirect target. Regarding the specific mechanism of action of AA, this 
agent indirectly inhibits AR activation by blocking the autocrine production of androgens 
67
, but at the 
same time, it has been postulated to have a direct effect on AA metabolites in the AR machinery 
68
. 
Finally, enzalutamide blocks three different levels of the AR machinery 
69
. On this basis, it could be 
hypothesised that the risk of cross-resistance could be higher by sequencing the two new-generation 
hormonal agents than by sequencing one taxane and one new hormonal agent, while the results of the 
TROPIC trial show that, at least in a proportion of patients, there is no cross-resistance between the two 
taxanes 
10
. 
Although no prospective trials support the increased risk of cross-resistance when AA and 
enzalutamide are sequentially administered, several observations  supported this finding. Recently, the 
investigators of the COU-AA-302 trial described the activity of post-progression therapies in patients 
treated in the AA experimental arm. The PFS of the patients who were treated with DOC as a first post-
progression treatment was 7.6 months 
70
, while those who received enzalutamide as a first post-
progression treatment was 2.8 months 
71
. A retrospective report described the outcomes of 546 patients 
who after first-line treatment with AA or enzalutamide received DOC or the other hormone agent not 
administered in the first-line setting: the clinical and PSA response rates at both 3 and 6 months clearly 
favoured DOC 
72
.   
A recently published systematic review and descriptive analysis explored the clinical outcomes of 
mCRPC patients who were treated with third-line new-generation hormonal agent after having 
previously received DOC and another new generation hormonal agent 
73
. This review, which analysed 
the survival plots of 13 studies (involving 1016 patients), suggested that in patients who had previously 
received first-line DOC, the use of CABA and a new hormonal agent in any order seemed to offer a 
greater OS advantage compared to the sequential administration of both new generation hormonal 
agents.  
More recently, an individual data analysis of more than 1,000 mCRPC patients treated with at least two 
life-prolonging agents after first-line DOC confirmed that after second-line treatment with a new 
hormonal agent, cabazitaxel may be more active than another new hormonal agent 
74
.  
Discussion 
The metastatic prostate cancer therapeutic landscape has dramatically evolved over the last decade: 
new clinical scenarios initiated by several trials, concluded in a very few years, made it difficult to 
translate the previous available evidence into current scenarios. For example, the TAX 327 trial proved 
the efficacy of DOC in chemo-naïve mCRPC patients in 2004, when none of the enrolled patients had 
previously received new-generation hormone agents, such AA or enzalutamide. Therefore, we do not 
have prospective data, based on randomised controlled studies, on DOC activity as a second-line 
treatment after the failure of AA or enzalutamide administered as a first-line treatment. Similarly, no 
prospective data can drive the therapeutic choice for mCSPC patients treated with AA or DOC who 
progress and become castration-resistant. 
Very limited observations were derived from reports concerning the post-progression therapies 
administered to the mCSPC patients enrolled in pivotal trials. The most accurate report on these 
treatments concerned the GETUG-AFU 15 trial and was recently published 
25
. Unfortunately, this 
report reflected the very limited availability of new-generation agents at the time the trial was 
conducted, since only 39 out of 111 evaluated patients in the DOC arm (35.1%) received such agents 
after castration-resistance development: 24 patients (21.6%) were treated with a DOC rechallenge, 10 
(9%) with one new-generation hormone agent, four (3.6%) with radium-223, and only one with 
cabazitaxel. It is clear that the retrospective nature of this report and the low number of patients 
evaluated did not allow definitive conclusions, reflecting not just a specific sequential strategy but 
more simply the availability of new agents in daily clinical practise, and did not help in driving the 
decision-making of clinicians when one patient treated with DOC in a mCSPC setting progressed and 
became castration-resistant.  
Nevertheless, in this context, the choice of therapy for the growing number of patients treated with 
DOC and ADT for mCSPC and progressing to mCRPC is something to urgently address in daily 
clinical practise. There are no parameters to guide clinical decision-making in this setting and no 
evidence to support decision-making in cases of high-risk mCSPC patients who will receive AA before 
progressing to mCRPC. However, some considerations may help clinicians in these two situations after 
one treatment for mCSPC: the current situation of treating patients after DOC, and the future situation 
of treating patients after AA.   
From a conceptual point of view, it is unclear whether mCSPC patients progressing after DOC should 
be considered similar to chemotherapy-naïve patients who should receive first-line mCRPC or similar 
to DOC pretreated mCRPC patients, who should receive second-line treatment. From a practical point 
of view, the lack of evidence from prospective controlled studies means that the choice of treatment 
can be driven only by personal feelings regarding drug activity based on pivotal trial data and everyday 
clinical experience.    
In our opinion, some suggestions based on experimental and clinical data on mCRPC patients could 
help and drive our choices.   
Suggestions for patients progressing after docetaxel administered in mCSPC 
The first decision driver could be the duration of disease control in mCSPC patients treated with DOC 
plus ADT: median PFS in the CHAARTED trial was 20.2 months in the DOC + ADT arm and 11.7 
months in the ADT arm. Accordingly, as patients whose PFS is > 20 months could conceivably have 
experienced the greatest benefit from DOC, they should be considered highly sensitive to the drug and, 
on the basis of cumulative experience with first-line DOC treatment for mCRPC, could be reasonably 
managed with a DOC rechallenge.   
In patients whose PFS is equal to or lower than the median observed in the CHAARTED control arm, 
especially those experiencing a PFS largely shorter than 20 months, the addition of DOC to ADT can 
be considered as bringing no relevant advantage, and DOC resistance can be hypothesised.  
As previously highlighted from a biological point of view, it can be thought that, in patients developing 
rapidly progressing mCRPC, the heterogeneity of cellular clones worsens, thus leading to an increase in 
resistance mechanisms by bypassing the androgen receptor pathway 
35
. From a clinical point of view, 
some published data suggest that AA and enzalutamide are less efficacious in patients whose disease is 
controlled by ADT for a shorter time. A post hoc analysis from COU-AA-301 showed lower AA 
activity after DOC in patients with ADT exposure at the lowest quartile 
75
. Similarly, data from real life 
suggested less efficacy of enzalutamide in patients achieving a shorter disease control with ADT 
76
. 
Because of these biological and clinical data, we believe that cabazitaxel could be considered the best 
therapeutic option for mCSPC patients relapsing within 12 months of DOC treatment, even if this 
consideration is not supported by a randomized clinical trial. Taxanes are capable of killing androgen 
receptor-negative tumoral cells but can also interfere with the androgen receptor signalling pathway
77
. 
Moreover, it is worth noting that, in the TROPIC trial, the survival advantage of cabazitaxel was also 
observed in patients whose disease progressed during DOC treatment and those with short PFS
10
. 
However, cabazitaxel as first line therapy in mCRPC patients failed to demonstrate an improvement in 
OS compared to docetaxel in the FIRSTANA trial.  
When PFS is between 12 and 20 months, PSA-DT may be a further guide for decision-making. PSA-
DT is related to the prognosis of mCRPC patients, as a shorter PSA-DT indicates shorter survival
55
. 
Although there is no established PSA-DT cut-off value to distinguish patients with different survival 
outcomes, a short PSA-DT is seen as a sign of aggressive disease and, consequently, it is widely 
accepted in the oncological community that chemotherapy should be the treatment of choice. 
Accordingly, we believe that patients with a PSA-DT ≤ 90 days should receive cabazitaxel and, in all 
other cases (for example, patients whose PFS is 12-20 months and PSA-DT > 90 days), the choice 
could consider all of the available agents (cabazitaxel, AA, enzalutamide, and radium-223), with 
prescribing limitations for radium-223 as it can be administered only to patients with symptomatic bone 
metastases without visceral or large nodal involvement. Of note, the Pharamacovigilance Risk 
Assessment Committee (PRAC) has recently recommended restricting the use of Radium-223 to 
patients who have had two previous treatments for mCRPC or who cannot receive other treatments 
78
. 
In clinical decision-making the choice of therapeutic options has to take into account patient 
characteristics. Although mCSPC patients treated with chemotherapy + ADT are all highly selected 
and capable of receiving six courses of DOC, the therapeutic choice may be influenced by 
comorbidities such as significant cardiovascular disease, diabetes, or a history of seizures. In addition, 
certain concomitant medications may interfere with the activity of new-generation hormonal agents. 
Finally, patient preferences also have to be considered as these may be influenced by the different 
toxicity profiles of the available agents, as well as by the burden of the side effects of previous DOC 
administration. 
Suggestions for patients progressing after abiraterone administered in mCSPC 
In patients who will be treated with AA for high-risk mCSPC and progress to mCRPC, we believe the 
growing evidence of the potential cross-resistance of AA and enzalutamide 
47,79,80
 should reasonably  
limit the choice between DOC and radium-223. According to recent PRAC restrictions 
78
, Radium 223 
should be considered only for symptomatic patients not eligible for docetaxel treatment, in the absence 
of large nodes and/or visceral metastases. 
Conclusions 
It is clear that the proposed algorithms do not reflect robust evidence from prospective trials or 
suggestions from real-life series. In developing our decision-making algorithm, we considered only 
some suggestions usually involved when choosing second-line mCRPC treatment. For example, we did 
not consider the Gleason score, which is usually viewed as a marker of aggressiveness, because we 
believe that patients with mCSPC at the time of diagnosis have aggressive disease regardless of their 
Gleason score. 
One final issue may further limit our proposal and the applicability of second-line mCRPC rules to 
mCSPC patients progressing after DOC or AA. We do not know whether the adaptive response of 
cancer cells to the drugs used to treat mCSPC is the same as that observed during the castration-
resistant phase of the disease or whether their response to subsequent agents is the same as that 
expected in mCRPC. However, despite the lack of evidence from prospective studies, we must propose 
a treatment for mCSPC patients progressing after DOC or AA, and our proposal may help in such 
everyday decision-making. 
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